OphtAI (Evolucare Technologies)

Villers-Bretonneux, France  All France companies → Founded 2019
Imaging AI Specialist Specialty-Focused AI
Bootstrapped — €26M (Evolucare Technologies)

About OphtAI (Evolucare Technologies)

OphtAI, a solution developed by the French group Evolucare Technologies, is a healthcare AI company specializing in ophthalmology. It offers large-scale automated screening for retinal diseases using artificial intelligence. The company’s AI analyzes retinal photos from a standard field color retinograph to detect the main pathological risks to the retina, specifically focusing on Diabetic Retinopathy, Glaucoma, and Age-related Macular Degeneration (AMD). The system provides results in seconds, including photo quality assessment, severity rating, location of detected lesions, and a confidence score, all compiled into a detailed PDF report.

OphtAI’s technology aims to address the challenges faced by modern ophthalmology, such as the increasing number of patients with chronic conditions and the scarcity of specialists. By enabling non-specialists to identify patients requiring priority care, OphtAI helps reduce the workload of ophthalmologists, allowing them to focus on therapeutic management. The solution is available via a web browser (OphtAI WEB), a desktop application (OphtAI APP), or through an API for integration into partner software. It is a CE-marked Class IIA medical device and has been developed through collaborative projects with AP-HP hospitals and the Latim research laboratory, utilizing a database of 800,000 retinal images.

Focus Areas

Diabetic Retinopathy Diabetic Macular Edema Age-related Macular Degeneration Glaucoma Retinal Disease Screening Artificial Intelligence in Ophthalmology Tele-ophthalmology

Business Intelligence

PartnershipsTopcon Healthcare, iCare (Revenio Group Corporation), Umami-Ware, Optomed, AP-HP, INSERM, ADCIS
TechnologyCloud-native, AI-powered image analysis, Deep Learning

What Physicians Need to Know

Specialization
OphtAI specializes in artificial intelligence (AI) tools for ophthalmology, focusing on the automated screening and detection of major retinal pathologies.
Key Pathologies Detected
Their AI algorithm can detect diabetic retinopathy (including its gradation), macular edema, glaucoma, and age-related macular degeneration (AMD) within seconds using a single color fundus image.
Accuracy & Performance
OphtAI's solution boasts high sensitivity and specificity in detecting retinal conditions, with performance comparable to, and in some cases outperforming, human experts.
Technology Stack
OphtAI offers various integration levels, including an Azure-hosted API (with on-premise installation available), URL contextual calls for browser-based access, and HTML components for displaying results.
Certifications
The OphtAI solution is a CE-marked medical device (Class IIA) and is certified by Health Canada.
Research & Development
OphtAI is the result of collaborative research with AP-HP (41 Public Hospitals) and the Latim research laboratory, drawing findings from a database of 800,000 retinas.
Physician Tip

For physicians, OphtAI offers an optimized workflow by providing automated preliminary patient sorting based on criticality and checking image quality to avoid re-examinations. The AI provides explicable results through lesion mapping and confidence indexes, helping to reduce the risk of error and identify early warning signs. It enables specialists to focus on complex cases and clinical care, while ensuring widespread and safe screening. The system can also contribute to automated patient record filling and offers customizable PDF reports. OphtAI aims to increase and expand expertise, improve productivity by delegating tasks, and facilitate multi-site organization and teleophthalmology networks.

OphtAI is designed for flexible integration into existing clinical workflows. It partners with platforms like Topcon's Harmony Referral System, a vendor-neutral data management platform, allowing access to OphtAI regardless of the color fundus device used. OphtAI's API allows for various integration levels, and it can be interfaced with most fundus cameras and ophthalmology specialty software. Specific integrations mentioned include Icare, CrystalVue, Area, Oplus, Optomed, Teo, TopCon, and UmamiView.

Products by OphtAI (Evolucare Technologies)

No products listed for this company yet. Know of one? Suggest it →

Reviews & Opinions

No web reviews on file yet for OphtAI (Evolucare Technologies). Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about OphtAI (Evolucare Technologies).

Loading videos...

Videos load interactively. If none appear, search YouTube for OphtAI (Evolucare Technologies) →

View all on YouTube

Press & Coverage

Evolucare
OphtAI: AI for ophthalmologists
This article discusses how AI, specifically OphtAI, is transforming ophthalmology by improving early detection and optimizing medical resources for conditions like diabetic retinopathy, glaucoma, and AMD.
2026-03
Evolucare
Evolucare OphtAI CE certified according to the MDR
OphtAI, a Class IIa medical device, obtained MDR certification, confirming its clinical reliability, technical robustness, and regulatory compliance for automated retinal image analysis.
2025-12
MFN.se (Revenio Group Corporation)
iCare and Evolucare have launched a distribution partnership in AI solutions
iCare and OphtAI, a French Evolucare Technologies company, have launched a distribution partnership. iCare will now offer OphtAI analysis in EMEA and Canada for its iCare ILLUME retinal screening solution based on retinal images.
2023-05
Topcon Healthcare
Topcon Healthcare and OphtAI Announce their Partnership in EMEA
Topcon Healthcare partnered with OphtAI to integrate OphtAI's AI algorithm for detecting eye pathologies into Topcon Harmony, their vendor-neutral data management platform.
2023-02
Optomed
Optomed signs an industrial partnership with a French AI company OphtAI
Optomed and OphtAI signed a commercial collaboration agreement to sell OphtAI's AI for screening common eye diseases with Optomed Aurora handheld cameras in Europe and Canada.
2022-03
Evolucare
OPHTAI CONFIRMS ITS UNRIVALED PERFORMANCE AND EFFICIENCY IN A REAL-WORLD VALIDATION STUDY PUBLISHED IN THE ADA DIABETES CARE JOU
A study published in ADA Diabetes Care journal validated OphtAI's performance in automatic assessment of Diabetic Retinopathy, showing it had the best sensitivity among participants and could reduce screening costs.
2021-01
Evolucare
EVOLUCARE puts the patient at the center of its thoughts
An interview with Evolucare CEO Philippe Blanco highlights OphtAI as a high-performing, inexpensive cloud-based AI solution for eye disease screening, developed in collaboration with APHP and Inserm.
2020-07
Evolucare
EVOLUCARE AND ADCIS ANNOUNCE THE CREATION OF OPHTAI, A JOINT VENTURE DEDICATED TO ARTIFICIAL INTELLIGENCE FOR OPHTHALMOLOGY, AT THE NEXT FRENCH OPHTHALMOLOGY SOCIETY CONVENTION
Evolucare and ADCIS announced the creation of OphtAI, a joint venture focused on AI for ophthalmology, aiming to develop innovative products for early detection of retinal diseases.
2019-05

Frequently Asked Questions

OphtAI offers an AI-powered software solution for automated screening of retinal pathologies. It is capable of detecting major retinal diseases such as diabetic retinopathy (including grading severity), diabetic macular edema, age-related macular degeneration (AMD), age-related maculopathy (early AMD), and glaucoma from fundus photographs.
OphtAI is a Class IIa medical device that has obtained MDR (Medical Device Regulation) certification in the European Union, is certified by Health Canada, and is registered under the UKCA. The solution is deployed with a certified health data hosting provider in France, complies with GDPR, and is designed to ensure security, traceability, and data protection by not storing patient-related data after processing.
OphtAI offers an unlimited, no-obligation subscription model with a 7-day free trial. It is accessible online via my.ophtai.com or through integration with existing business software, suggesting flexibility for various practice sizes and healthcare systems.
While specific details on support and implementation assistance are not extensively detailed, OphtAI aims to make AI accessible and easy to use in everyday practice. The solution can be deployed in various settings, including healthcare facilities, private practices, and teleophthalmology, and is compatible with basic infrastructure. Evolucare, the parent company, emphasizes its strong teams with functional and technical expertise to ensure smooth implementation and operations.
Yes, OphtAI has established several partnerships. Notably, it has a distribution partnership with iCare (Revenio Group Corporation) to offer OphtAI analysis in EMEA and Canada for iCare ILLUME retinal screening solutions. OphtAI was also developed in collaboration with ADCIS and is a result of a public-private R&D partnership with organizations like AP-HP hospitals and the Latim research laboratory. They also partner with Umami-Ware to promote the OphtAI solution in the German market.
OphtAI is a joint venture created by Evolucare and ADCIS, both established companies in healthcare IT and image analysis, respectively. Evolucare, founded over 35 years ago, is a leading French group in the Medical IT market with about 500 employees and 18 offices across several countries. The Evolucare Group recently joined the Italian GPI Group in mid-2023, which aims to accelerate its international deployment. OphtAI's ambition is to become an essential reference in the AI market for ophthalmology, with ongoing efforts for FDA approval to target the American market.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.